SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024. Late Breaker - Oral and ePoster Presentations Title: Evaluation of the ant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4272481 (State or other jurisdiction of (I. ...

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS-PSC 320 mg dose group demonstrated bexotegrast was well tolerated with continued antifibrotic and anti-cholestatic activity observed at 24 weeks across multiple measures BEACON-IPF Phase ...

Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events Statistically significant improvement in alkaline phosphatase (ALP) levels over 24 weeks compared to placebo Continued improvement in hepatocyte function and bile flow by contrast MRI imaging observed from Week 12 to Week 24 SOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced positive 24-week data from the 320 mg co ...

"Steve is a tremendous addition to our board, bringing extensive strategic leadership experience and a depth of financial expertise that will benefit Pliant's continued evolution as a late-stage clinical company," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "Steve's broad financial experience will be highly complimentary to the strong science and business expertise on the board. We look forward to his insights." Pliant Therapeutics is a late-stage biopharmaceutical com ...

SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee Yun, M.D., the Company's newly appointed Senior Vice President of Clinical Development as a material inducement to her employment. The stock options that were granted are subject to an exercise price of $11.51 per share, which is equal to the closing price of t ...

SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, were presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held June 5-8, 2024. "We were pleased to share our latest data from our bexotegrast p ...

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024. "Our 2024 ATS presentations include compreh ...

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024. "Our 2024 ATS presentations include compreh ...

12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared to placebo Bexotegrast 160 mg was well tolerated over 12 weeks of treatment with no serious adverse events and no discontinuations SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today ann ...